Jarmo S. Salonen

CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen et al. · PubMed · 2001 · 91 citations

Medicine, Pharmacokinetics, Pharmacology +17

Regio- and Stereospecific N-Glucuronidation of Medetomidine: The Differences between UDP Glucuronosyltransferase (UGT) 1A4 and UGT2B10 Account for the Complex Kinetics of Human Liver Microsomes

Sanna Kaivosaari, Päivi Toivonen, Olli Aitio et al. · Drug Metabolism and Disposition · 2008 · 71 citations

Medicine, Biochemistry, Pharmacology +10

COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS

Jarmo S. Salonen, Leena Nyman, Alan R. Boobis et al. · Drug Metabolism and Disposition · 2003 · 67 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Selegiline Metabolism and Cytochrome P450 Enzymes:In vitro Study in Human Liver Microsomes*

Päivi Taavitsainen, Markku Anttila, Leena Nyman et al. · Pharmacology & Toxicology · 2000 · 53 citations

Medicine, Pharmacology, Toxicology +17

Biotransformation of medetomidine in the rat

Jarmo S. Salonen, Maire Eloranta · Xenobiotica · 1990 · 32 citations

Pharmacy, Pharmacokinetics, Pharmacology +16